|
ALZHEIMER DISEASE 5
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Importantly, <i>in vitro</i> synthesized VA RNAI was able to inhibit the NLRP3 inflammasome activity in THP-1 cells in the absence of an Ad5 infection, suggesting that VA RNAI binding to PKR and blocking its function is sufficient for inhibition of the NLRP3 inflammasome.
|
31849970 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NLRP3 Inflammasome Mediated Interleukin-1β Production in Cancer-Associated Fibroblast Contributes to ALA-PDT for Cutaneous Squamous Cell Carcinoma.
|
31849516 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
NLRP3 Inflammasome Mediated Interleukin-1β Production in Cancer-Associated Fibroblast Contributes to ALA-PDT for Cutaneous Squamous Cell Carcinoma.
|
31849516 |
2019 |
|
Squamous cell carcinoma of skin
|
0.010 |
Biomarker
|
disease |
BEFREE |
By means of activating NLRP3-inflammasome with IL1β production in CAFs, PDT stimulates local acute-inflammatory-response, which further promotes PDT effect for cSCC.
|
31849516 |
2019 |
|
Small Intestinal Mucositis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to determine the role of the NLRP3 inflammasome in 5-FU-induced small intestinal mucositis.
|
31846964 |
2019 |
|
Ureteral obstruction
|
0.090 |
GeneticVariation
|
phenotype |
BEFREE |
Here, C57/BL6 mice were allocated to Sham and unilateral ureteral obstruction (UUO) groups, which were treated with NaHS or NLRP3 inflammasome inhibitor 16673-34-0 for 3-14 days.
|
31846625 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-mediated inflammatory infiltration was determined to participate in NAFLD.
|
31841118 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, a variety of researches have focused on exploring new therapies, and found that natural products (NPs) that isolated from herbs or plants may serve as promising therapeutic agents for IBD through anti-inflammatory, anti-oxidant, anti-fibrotic and anti-apoptotic effects, which implicates the modulation on nucleotide-binding domain (NOD) like receptor protein (NLRP) 3 inflammasome, gut microbiota, intestinal microvascular endothelial cells, intestinal epithelia, immune system, etc.
|
31840596 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, NLRP3 inflammasome can suppress FMDV replication during virus infection.
|
31840571 |
2020 |
|
Foot-and-Mouth Disease
|
0.010 |
Biomarker
|
group |
BEFREE |
NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B.
|
31840571 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Previous work has reported the closely correlation between inflammation and carcinogenesis, while the role of NALP3, the key component of inflammasome activation in NSCLC remains elusive.
|
31838136 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We reported NALP3 were up-regulated in NSCLC tumor tissues.
|
31838136 |
2020 |
|
Vasculitis
|
0.120 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the role of NLRP3 inflammasome in a murine model of KD induced by Candida albicans water-soluble fraction (CAWS) and found that NLRP3 inflammasome is required for the development of CAWS-induced vasculitis.
|
31836541 |
2020 |
|
Mucocutaneous Lymph Node Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings provide new insights into the pathogenesis of KD vasculitis, and suggest that NLRP3 inflammasome may be a potential therapeutic target for KD.
|
31836541 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
As such, further study of the interaction between the NLRP3 inflammasome and the complex intestinal environment in disease development is warranted to discover novel therapies for the treatment of diabetes.
|
31835423 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
As such, further study of the interaction between the NLRP3 inflammasome and the complex intestinal environment in disease development is warranted to discover novel therapies for the treatment of diabetes.
|
31835423 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes the regulation of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) by NLRP3 via modulation of glucose tolerance, insulin resistance, inflammation, and apoptosis mediated by endoplasmic reticulum stress in adipose tissue.
|
31835423 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.060 |
Biomarker
|
disease |
BEFREE |
This review summarizes the regulation of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) by NLRP3 via modulation of glucose tolerance, insulin resistance, inflammation, and apoptosis mediated by endoplasmic reticulum stress in adipose tissue.
|
31835423 |
2019 |
|
Septicemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
NLRP3 inflammasome and RhoA contribute to sepsis and intestinal inflammation.
|
31835087 |
2020 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
NLRP3 inflammasome and RhoA contribute to sepsis and intestinal inflammation.
|
31835087 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.
|
31834465 |
2020 |
|
Cerebral Infarction
|
0.070 |
Biomarker
|
disease |
BEFREE |
Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation.
|
31830477 |
2020 |
|
Middle Cerebral Artery Occlusion
|
0.070 |
Biomarker
|
disease |
BEFREE |
Nlpr3<sup>-/-</sup> mice, Gpr40<sup>-/-</sup>; Gpr120<sup>-/-</sup> mice and mice with right middle cerebral artery occlusion (MCAO) were used to detect NLR family pyrin domain containing 3 (NLRP3) inflammasome activation by Western Blot and the release of proinflammatory cytokines by ELISA.
|
31830477 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this prospective study, we aim to explore the role of angiotensin II (Ang II) and NLRP3 inflammasome in NAFLD patients.
|
31827504 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data clearly indicate that MR and NLRP3 activation contribute to diabetes-associated vascular dysfunction and pro-inflammatory phenotype.
|
31817997 |
2019 |